Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.51 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.51 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440743 | 0.79 | GRIA1 (0.50) | GRIA1GRIA2GRIA3GRIA4KMT2A | |
| SCHEMBL4258057 | 0.78 | ACHE (0.44) | KMT2AKDM4EGAAALDH1A1 | |
| SCHEMBL3454882 | 0.77 | PRMT5 (0.50) | GRIA1GRIA2GRIA3GRIA4KMT2A | |
| SCHEMBL29310333 | 0.72 | MAOA (0.41) | CHRM1MAOAMAOBSLC6A4CYP1A2 | |
| SCHEMBL22859030 | 0.72 | GRIA1 (0.51) | GRIA1GRIA2GRIA3GRIA4KMT2A | |
| SCHEMBL31213749 | 0.72 | GRIA1 (0.43) | GRIA1GRIA2GRIA3GRIA4LMNA | |
| SCHEMBL29310310 | 0.71 | KDM4E (0.42) | KDM4EMAOAMAOBSLC6A4CYP1A2 | |
| SCHEMBL20214765 | 0.71 | MAOA (0.40) | MAOAMAOBSLC6A4CYP1A2CYP2D6 | |
| SCHEMBL14287199 | 0.69 | GABRA1 (0.47) | GRIA1GRIA2GRIA3GRIA4KMT2A | |
| SCHEMBL22859092 | 0.69 | PRMT5 (0.47) | GRIA1GRIA2GRIA3GRIA4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2051975-B1 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INT (DE) | 2012-09-12 | — | — | EP | disclosed |
| US-7807693-B2 | Substituted prolinamides, manufacturing, and the use thereof as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-05 | — | — | US | disclosed |
| EP-2051975-A2 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | Boehringer Ingelheim International GmbH (DE) | 2009-04-29 | — | — | EP | disclosed |
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIN INTERNATIONAL GMBH (DE) | 2008-06-12 | — | — | US | disclosed |
| WO-2007131982-A2 | SUBSTITUTED PROLINAMIDES, PRODUCTION THEREOF AND THEIR USE AS DRUGS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139605-A1 | SUBSTITUTED PROLINAMIDES, MANUFACTURING, AND THE USE THEREOF AS MEDICAMENTS | PPID, PREP, P4HA1 | GRIA1 1333/4885GRIA2 1490/4885GRIA3 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.